#53493 05-11-2004 05:45 AM | Joined: Feb 2004 Posts: 162 Gold Member (100+ posts) | OP  Gold Member (100+ posts)
Joined: Feb 2004 Posts: 162 | Here's some of the data I have:
Prevention of Second Primary Tumors with Isotretinion (13-cis-retinoic acid) (9/20/1990):
Results: There were no significant differences between the two groups (medication & placebo) in the number of local, regional or distant recurrences of the primary cancers. However, the isotretinion had significantly fewer second primary tumors. After a median follow up of 32 months, only 4% of the isotretinion group had SPT's as compared with 12% of the placebo group.
Conclusions: Daily treatment with high doses of isotretinion is effective in preventing SPT's in patients who have been treated for SCC of the head and neck, although it does not prevent recurrences of the original tumor.
The other studies I have involve more than one agent -- interferon and 13-cis-retinoic acid.
-Brett
Base of Tongue SCC. Stage IV, T1N2bM0. Diagnosed 25 July 2003.
Treated with 6 weeks induction chemo -- Taxol & Carboplatin once a week followed with 30 fractions IMRT, 10 fields per fraction over 6 more weeks. Recurrence October 2005.
| | |
#53494 05-11-2004 04:53 PM | Joined: Mar 2002 Posts: 4,912 Likes: 52 OCF Founder Patient Advocate (old timer, 2000 posts) | | OCF Founder Patient Advocate (old timer, 2000 posts)
Joined: Mar 2002 Posts: 4,912 Likes: 52 | Brett...Please be sure to post the source of the data, where it was published etc. if you wish for it to stay on the board. Also remember that data which is four years old, may be still accurate or may not reflect the most current thinking in all things. This is a field where discoveries and trial results appear on a daily basis. What we knew four years ago may have been now superceded by something different. Posting references allows all to judge for themselves, and reading the original study in it's complete form, to determine if the information is still of value, appropriate for them, something to bring up to their docs etc.
Brian, stage 4 oral cancer survivor. OCF Founder and Director. The first responsibility of a leader is to define reality. The last is to say thank you. In between, the leader is a servant.
| | |
#53495 05-12-2004 06:13 AM | Joined: Feb 2004 Posts: 162 Gold Member (100+ posts) | | OP Gold Member (100+ posts)
Joined: Feb 2004 Posts: 162 | I was worried about making some sort of mistake in posting this. That information was published in the New England Journal of Medicine 9/29/90 of which I was provided a xerox copy of just the study data. I'm not about to retype the entire document. I'll refrain from this type of post in the future. Please go ahead and kill this thread if you think that is the right thing to do.
-Brett
Base of Tongue SCC. Stage IV, T1N2bM0. Diagnosed 25 July 2003.
Treated with 6 weeks induction chemo -- Taxol & Carboplatin once a week followed with 30 fractions IMRT, 10 fields per fraction over 6 more weeks. Recurrence October 2005.
| | |
| Forums23 Topics18,168 Posts196,924 Members13,103 | | Most Online458
Jan 16th, 2020 | | |
|
